OtherResearch Market

Testagen

A synthetic tetrapeptide (Lys-Glu-Asp-Gly) from the Khavinson bioregulator family, studied for testicular tissue bioregulation and age-related hormonal support.

TestosteroneMen's HealthBioregulatorKhavinson

Also referenced as: KEDG, Lys-Glu-Asp-Gly

Also appears in: Longevity

Price compare
26 tracked offers across 26 vendors · 10 dosages
Best trust-adjusted value: Peptide Supply Co · Strong trust · $1.89/mg
From
$1.78/mg
Tracked market history

What has the price actually done?

Daily, exact-comparability offers. Discounts use the terms known on each historical date.

Flatvs. Aug 10
Current low$1.89/mg
Market median$2.70/mg
Current coverage12 vendors
Observed window90 daily points
Lowest effective priceMarket median
Compare current offers
How this history is calculated

Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when Testagen crosses your target, drops, or sets a new tracked low—without daily noise.

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.
Public product evidence22 certificate records mentioning this compound or product name11 provider-linked · 20 exact product matches
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
Other research areas

Primary research area: Other. Also surfaces under Longevity for browsing and discovery.

Aliases
2

KEDG, Lys-Glu-Asp-Gly

Signal depth
Low

No FDA label signal · 1 trials · 13 PubMed results

Early
Research evidence

Testagen has human trials registered, but none have reported controlled results yet. Most current claims about what it does in people rest on preclinical (lab or animal) work, not published human data.

Testagen has 1 name-matched clinical trial (highest phase: Phase 2) and 13 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.

Human data
Phase 2
Trial quality
Randomized
Outcomes
Surrogate / early
Replication
Multiple papers
Literature
Established
PHASE2 · RandomizedProduct Transference Study of Testagen™ TDS®-TestosteroneUS Army Corps of Engineers: Engineer Research and Development Center (Knowledge Core) · 4 citationsTOWING SHIPS THROUGH ICE-CLOGGED CHANNELS BY WARPING AND KEDGINGBulletin of Experimental Biology and Medicine · 3 citationsEffect of tetrapeptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the structure and function of the thyroid gland in neonatally hypophysectomized chickensMolecules · 1 citationsThe Inhibitory Effect and Adsorption Properties of Testagen Peptide on Copper Surfaces in Saline Environments: An Experimental and Computational StudyJournal ArticleFeasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters.Journal ArticlePeptide Regulation of Cell Differentiation.
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What is Testagen?

Testagen is a synthetic tetrapeptide with the sequence Lys-Glu-Asp-Gly (KEDG), developed as part of the Khavinson bioregulator peptide program. It is classified as a testicular-tissue bioregulator, theorized to support age-related testicular function through tissue-specific gene modulation.

How it works

  • Peptide-DNA interaction — short peptides are proposed to penetrate cell nuclei and interact with gene promoter regions, modulating transcription in a tissue-specific manner (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2011)
  • Hormonal support — Testagen is theorized to support endogenous testosterone-related pathways in aging testicular tissue, though specific gene targets have not been identified in Western peer-reviewed literature

Research status

  • Khavinson (2005) reviewed the broader peptide bioregulator program (Gerontology, 51(2):70–75)
  • Anisimov et al. (2003) reported geroprotective effects of bioregulator peptide preparations in rodent models (Annals of the New York Academy of Sciences, 992:141–147)
  • No specific Western peer-reviewed clinical trials for Testagen have been published

Key considerations

  • Part of the Khavinson bioregulator family — same proposed mechanism as Prostamax, Pinealon, Cartalax, and others
  • Research originates from a single group with limited independent replication
  • Available from research vendors as lyophilized powder or capsules (typically 10–20mg)
  • Not to be confused with pharmaceutical testosterone replacement therapies